Company Overview and News

Teejay Lanka to make US $ 13mn investment in India next year

Teejay Marketing and Business Development Chief Operating Officer Rodney Arland, Teejay Non-Executive Director and Brandix Lanka Ltd CFO Hasitha Premaratne, Teejay CEO Sriyan de Silva Wijeyeratne, Teejay Group Chairman Bill Lam and Teejay Corporate Communications Head Samadhi Weerakoon

Textured Jersey executives meet investment funds in U.S.

2016-09-19 lankabusinessonline
Sept 19, 2016 (LBO) – Textured Jersey Lanka PLC executives Moiz Rehmanjee and Rodney Arland were in the U.S. last week to meet global investment funds, as part of a non-deal roadshow.

Textured Jersey & Brandix Fast Fashion are 2016 ‘Mercury Trophy’ Volleyball champs

Virtuoso volleyball was on display when teams from Textured Jersey Lanka PLC (TJL) and Brandix Fast Fashion Mirigama won the Men’s and Women’s finals of the annual ‘Rasadiya Kusalanaya’ (Mercury Trophy) Volleyball Tournament conducted by the Brandix Group at the Sugathadasa Indoor Stadium.

Textured Jersey Lanka net up 93-pct; best 1Q to date

2016-07-29 lankabusinessonline
The TJL Group (TJ), who closed the last financial year on a resounding note, continued its performance momentum in the new financial year, reporting eight straight quarters of strong quarterly profit growth. The Q1 2016/17 performance has proved to be the Group’s best first quarter recorded to date, posting a consolidated net profit of Rs. 399 Million, representing a YoY growth of 93 percent.

Textured Jersey Lanka net up 79-pct in Dec quarter

2016-02-03 lankabusinessonline
Feb 03, 2016 (LBO) – Profits at Textured Jersey Lanka, a fabric maker, rose to 672 million rupees in the December 2015 quarter up 79 percent from a year earlier, the firm said. Textured Jersey repo...

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

20h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...